Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHA:605016)
China · Delayed Price · Currency is CNY 21.38
+0.21 (0.99%)
Sep 14, 2026, 3:00 PM CST
SHA:605016 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,468 | 1,345 | 1,107 | 854.14 | 696.18 | 638.52 |
Other Revenue | 21.61 | 34.32 | 45 | 14.12 | 25.71 | 14.83 |
| 1,489 | 1,379 | 1,152 | 868.26 | 721.89 | 653.36 | |
Revenue Growth | 17.32% | 19.75% | 32.64% | 20.28% | 10.49% | 30.77% |
Cost of Revenue | 847.26 | 805.73 | 764.89 | 584.2 | 493.41 | 471.72 |
Gross Profit | 642.07 | 573.32 | 386.76 | 284.06 | 228.49 | 181.64 |
Selling, General & Admin | 82.97 | 79.86 | 67.54 | 47.77 | 45.05 | 40.35 |
Research & Development | 50.61 | 48.82 | 44.46 | 32.56 | 27.03 | 23.26 |
Other Operating Expenses | 10.91 | 8.07 | 9.62 | 7.61 | 5.99 | 5.67 |
Operating Expenses | 146.67 | 141.56 | 127.86 | 90.61 | 82.81 | 71.65 |
Operating Income | 495.4 | 431.77 | 258.9 | 193.45 | 145.68 | 109.98 |
Interest Expense | -3.9 | -5.77 | -2.66 | -2.25 | -0.07 | -1.04 |
Interest & Investment Income | 9.65 | 14.64 | 9.61 | 12.14 | 12.76 | 5.04 |
Currency Exchange Gain (Loss) | -10.24 | -10.02 | 8.17 | 4.13 | 10.28 | -2.76 |
Other Non Operating Income (Expenses) | -12.14 | -0.79 | -0.43 | -0.21 | -0.13 | -0.14 |
EBT Excluding Unusual Items | 478.79 | 429.82 | 273.59 | 207.27 | 168.52 | 111.09 |
Gain (Loss) on Sale of Investments | -1.65 | -0.79 | 1.27 | 2.7 | 0 | 3.35 |
Gain (Loss) on Sale of Assets | -2.55 | -7.23 | -0.39 | -2.13 | -3.15 | -1.26 |
Asset Writedown | -2.34 | - | - | - | - | -1.73 |
Other Unusual Items | 5.61 | 10.48 | 10.83 | 13.68 | 7.71 | 7.32 |
Pretax Income | 477.85 | 432.27 | 285.31 | 221.52 | 173.09 | 118.77 |
Income Tax Expense | 68.44 | 63.72 | 39.71 | 28.52 | 22.34 | 14.29 |
Net Income | 409.4 | 368.55 | 245.6 | 193 | 150.75 | 104.48 |
Net Income to Common | 409.4 | 368.55 | 245.6 | 193 | 150.75 | 104.48 |
Net Income Growth | 38.40% | 50.06% | 27.26% | 28.02% | 44.29% | 9.34% |
Shares Outstanding (Basic) | 417 | 419 | 423 | 418 | 418 | 385 |
Shares Outstanding (Diluted) | 417 | 419 | 423 | 418 | 418 | 385 |
Shares Change | -1.97% | -1.09% | 1.26% | 0.12% | 8.63% | 22.70% |
EPS (Basic) | 0.98 | 0.88 | 0.58 | 0.46 | 0.36 | 0.27 |
EPS (Diluted) | 0.98 | 0.88 | 0.58 | 0.46 | 0.36 | 0.27 |
EPS Growth | 41.19% | 51.72% | 25.68% | 27.88% | 32.83% | -10.89% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 8.19 | -161.35 | 19.09 | -117.34 | -25.78 | 40.38 |
Free Cash Flow Per Share | 0.02 | -0.39 | 0.04 | -0.28 | -0.06 | 0.10 |
Dividend Per Share | 0.215 | 0.265 | 0.146 | 0.142 | 0.072 | 0.026 |
Dividend Growth | 24.21% | 81.26% | 2.96% | 97.50% | 180.86% | - |
Gross Margin | 43.11% | 41.57% | 33.58% | 32.72% | 31.65% | 27.80% |
Operating Margin | 33.26% | 31.31% | 22.48% | 22.28% | 20.18% | 16.83% |
Profit Margin | 27.49% | 26.72% | 21.33% | 22.23% | 20.88% | 15.99% |
Free Cash Flow Margin | 0.55% | -11.70% | 1.66% | -13.51% | -3.57% | 6.18% |
EBITDA | 590.68 | 528.62 | 334.42 | 238.38 | 192.42 | 156.51 |
EBITDA Margin | 39.66% | 38.33% | 29.04% | 27.46% | 26.66% | 23.96% |
D&A For EBITDA | 95.27 | 96.86 | 75.52 | 44.93 | 46.75 | 46.53 |
EBIT | 495.4 | 431.77 | 258.9 | 193.45 | 145.68 | 109.98 |
EBIT Margin | 33.26% | 31.31% | 22.48% | 22.28% | 20.18% | 16.83% |
Effective Tax Rate | 14.32% | 14.74% | 13.92% | 12.88% | 12.91% | 12.04% |
Revenue as Reported | 729.87 | 1,379 | 1,152 | 868.26 | 721.89 | 653.36 |
Advertising Expenses | - | 5.05 | 3.48 | 2.9 | 1.13 | 1.25 |